AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23922184 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with non‐ablative fractional laser and optimized intense pulsed light (Group A)
Number of subjects: 36
Study 23922184 — intervention group
Group type: COMPARATOR
Intervention: Non‐ablative fractional laser only (Group B)
Number of subjects: 36
Study 22512098 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MIS)
Number of subjects: 96
Study 22512098 — intervention group
Group type: COMPARATOR
Intervention: Classical approach
Number of subjects: 96
Study 19258204 — intervention group
Group type: EXPERIMENTAL
Intervention: LAAM
Number of subjects: 53
Study 19258204 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 53
Study 17883994 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacologic therapy including cardiac resynchronization therapy, left ventricular assist devices, and cardiac rehabilitation
Number of subjects: 0
Study 17883994 — intervention group
Group type: COMPARATOR
Intervention: Interventions aimed at treatment of acute HF syndromes
Number of subjects: 0
Study 17883994 — intervention group
Group type: COMPARATOR
Intervention: General interventions for HF
Number of subjects: 0
Study 15248853 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-IgE treatment
Number of subjects: 225
Study 15248853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 15635850 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on a bicycle ergometer three times per week for eight weeks, 30 minutes per session at the level of the anaerobic threshold.
Number of subjects: 38
Study 15635850 — intervention group
Group type: COMPARATOR
Intervention: Control group (K)
Number of subjects: 38
Study 10396235 — intervention group
Group type: EXPERIMENTAL
Intervention: Microimmunofluorescence test (MIF) for IgG, IgM, and IgA antibodies to C pneumoniae
Number of subjects: 1020
Study 10396235 — intervention group
Group type: EXPERIMENTAL
Intervention: Time resolved fluoroscopic immunoassay (TRIA) for IgG antibodies to C pneumoniae
Number of subjects: 1020
Study 2072003 — intervention group
Group type: EXPERIMENTAL
Intervention: H tone setting with a 2 mm vented mould
Number of subjects: 83
Study 2072003 — intervention group
Group type: COMPARATOR
Intervention: Standard hearing aid settings
Number of subjects: 83
Study 6338993 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lignocaine gel alone
Number of subjects: 82
Study 6338993 — intervention group
Group type: COMPARATOR
Intervention: 2% lignocaine gel with St Mark's Hospital anal dilator
Number of subjects: 82
Study 6338993 — intervention group
Group type: COMPARATOR
Intervention: No operation for anterior or lateral anal fissures
Number of subjects: 82
Study 30895313 — intervention group
Group type: EXPERIMENTAL
Intervention: Large cage (160 × 160 × 62 cm; LC)
Number of subjects: 575
Study 30895313 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium cage (120 × 120 × 62 cm; MC)
Number of subjects: 575
Study 30895313 — intervention group
Group type: COMPARATOR
Intervention: Small cage (80 × 70 × 62 cm; SC)
Number of subjects: 575
Study 30895313 — intervention group
Group type: EXPERIMENTAL
Intervention: Large cage (LC)
Number of subjects: 575
Study 30895313 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium cage (MC)
Number of subjects: 575
Study 30895313 — intervention group
Group type: COMPARATOR
Intervention: Small cage (SC)
Number of subjects: 575
Study 30072400 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg/day)
Number of subjects: 9340
Study 30072400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9340
Study 27044340 — intervention group
Group type: EXPERIMENTAL
Intervention: Icon-based menu labelling initiative
Number of subjects: 8
Study 27044340 — intervention group
Group type: COMPARATOR
Intervention: Control (no icon-based menu labelling)
Number of subjects: 8
Study 23714321 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based questionnaire
Number of subjects: 118
Study 23714321 — intervention group
Group type: COMPARATOR
Intervention: Paper-and-pencil questionnaire
Number of subjects: 118
Study 21392601 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infusion of abciximab after aspiration with a 6F Export Aspiration Catheter
Number of subjects: 452
Study 21392601 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infusion of abciximab and no aspiration
Number of subjects: 452
Study 21392601 — intervention group
Group type: EXPERIMENTAL
Intervention: No local infusion of abciximab and aspiration with a 6F Export Aspiration Catheter
Number of subjects: 452
Study 21392601 — intervention group
Group type: COMPARATOR
Intervention: No local infusion of abciximab and no aspiration
Number of subjects: 452
Study 21392601 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 452
Study 19707840 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Intervention (SI)
Number of subjects: 63
Study 19707840 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 63
Study 19707840 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior low-risk drinking status at 12 months
Number of subjects: 63
Study 17311617 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 1 mg/day for 6 months
Number of subjects: 10
Study 15522379 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained decrease of visual field (SDVF) defined as a worsening from baseline by 4 units sustained for 3 consecutive 6-month visits
Number of subjects: 565
Study 15522379 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained decrease of visual field (SDVF) with a worsening of at least 2 units
Number of subjects: 565
Study 15522379 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmatory tests after a sustained event
Number of subjects: 565
Study 15522379 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean deviation (MD) worsening
Number of subjects: 565
Study 11503945 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine bromide (30 mg orally)
Number of subjects: 17
Study 11503945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 10073847 — intervention group
Group type: EXPERIMENTAL
Intervention: Open infarct-related artery
Number of subjects: 11228
Study 10073847 — intervention group
Group type: COMPARATOR
Intervention: Closed infarct-related artery
Number of subjects: 11228
Study 8006252 — intervention group
Group type: EXPERIMENTAL
Intervention: Angina-guided medical strategy
Number of subjects: 618
Study 8006252 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemia-guided medical strategy
Number of subjects: 618
Study 8006252 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization strategy
Number of subjects: 618
Study 8006252 — intervention group
Group type: COMPARATOR
Intervention: All strategies
Number of subjects: 618
Study 2734234 — intervention group
Group type: COMPARATOR
Intervention: Abnormal uterine bleeding (when dead controls were used)
Number of subjects: 148
Study 2734234 — intervention group
Group type: EXPERIMENTAL
Intervention: Placenta praevia (when live controls were used)
Number of subjects: 148
Study 2734234 — intervention group
Group type: EXPERIMENTAL
Intervention: Abruptio placentae (when live controls were used)
Number of subjects: 148
Study 2734234 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple birth (when live controls were used)
Number of subjects: 148
Study 2734234 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy interval ≤ 12 months (when live controls were used)
Number of subjects: 148
Study 2734234 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexually transmitted disease (when live controls were used)
Number of subjects: 148
Study 2734234 — intervention group
Group type: EXPERIMENTAL
Intervention: Eclampsia (when live controls were used)
Number of subjects: 148
Study 22216509 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (75-300 mg) in combination with chlorthalidone
Number of subjects: 23
Study 22216509 — intervention group
Group type: COMPARATOR
Intervention: Placebo in combination with chlorthalidone
Number of subjects: 23
Study 29709447 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent Inactivated Vaccine (QIV)
Number of subjects: 1980
Study 27142356 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous aminophylline
Number of subjects: 0
Study 27142356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25787041 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring and office follow-up
Number of subjects: 374
Study 25787041 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring without physician office care
Number of subjects: 374
Study 25787041 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical care with home BP monitoring (Control)
Number of subjects: 374
Study 24090047 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 300
Study 24090047 — intervention group
Group type: EXPERIMENTAL
Intervention: Blonanserin
Number of subjects: 300
Study 24090047 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone
Number of subjects: 300
Study 21699786 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir (750 mg every 8 h)
Number of subjects: 49
Study 21699786 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir + Peginterferon + Ribavirin (TPR)
Number of subjects: 49
Study 21699786 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon + Ribavirin (PR)
Number of subjects: 49
Study 21699786 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir
Number of subjects: 49
Study 17927991 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care intervention in somatic wards
Number of subjects: 9
Study 17927991 — intervention group
Group type: COMPARATOR
Intervention: Control wards (psycho-geriatric)
Number of subjects: 9
Study 16503678 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 x 1 repetition with 20‐second rest periods (Singles)
Number of subjects: 26
Study 16503678 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 2 repetitions with 50 seconds rest (Doubles)
Number of subjects: 26
Study 16503678 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x 3 repetitions with 100 seconds rest (Triples)
Number of subjects: 26
Study 16503678 — intervention group
Group type: EXPERIMENTAL
Intervention: All interrepetition rest interventions
Number of subjects: 26
Study 16503678 — intervention group
Group type: COMPARATOR
Intervention: Traditional continuous 6RM total power output
Number of subjects: 26
Study 14577025 — intervention group
Group type: EXPERIMENTAL
Intervention: levobupivacaine 0.5%
Number of subjects: 57
Study 14577025 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine 1%
Number of subjects: 57
Study 14577025 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline solution (Placebo)
Number of subjects: 57
Study 11284975 — intervention group
Group type: EXPERIMENTAL
Intervention: Reservoir technique
Number of subjects: 139
Study 11284975 — intervention group
Group type: EXPERIMENTAL
Intervention: Globe technique
Number of subjects: 139
Study 9356529 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea (900 mL/d)
Number of subjects: 45
Study 9356529 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea (900 mL/d)
Number of subjects: 45
Study 9356529 — intervention group
Group type: COMPARATOR
Intervention: Control (900 mL mineral water/d)
Number of subjects: 45
Study 9356529 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro experiment with high amounts of green or black tea
Number of subjects: 45
Study 8487564 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade cardioplegia
Number of subjects: 60
Study 8487564 — intervention group
Group type: COMPARATOR
Intervention: Retrograde cardioplegia
Number of subjects: 60
Study 8487564 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 2959307 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 36
Study 2959307 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 36
Study 2959307 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ipratropium and salbutamol
Number of subjects: 36
Study 2959307 — intervention group
Group type: COMPARATOR
Intervention: Control (rimiterol)
Number of subjects: 36
Study 30527100 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative implementation strategy including a computerized decision support system (DSS) and professional audit and feedback
Number of subjects: 0
Study 30527100 — intervention group
Group type: COMPARATOR
Intervention: Minimal implementation strategy of audit and feedback only
Number of subjects: 0
Study 26708287 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (duration <1 year)
Number of subjects: 98
Study 26708287 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (duration 1-5 years)
Number of subjects: 98
Study 26708287 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (duration >5 years)
Number of subjects: 98
Study 26708287 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of metabolic syndrome
Number of subjects: 98
Study 26708287 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher body mass index
Number of subjects: 98
Study 26708287 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher lipoprotein(a)
Number of subjects: 98
Study 25622681 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal lignocaine/phenylephrine
Number of subjects: 100
Study 25622681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 25927562 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical Time Intervention (CTI)
Number of subjects: 0
Study 25927562 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual
Number of subjects: 0
Study 21609555 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic surgery by infraclavicular approach
Number of subjects: 42
Study 21609555 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach
Number of subjects: 42
Study 18313688 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm weights
Number of subjects: 0
Study 18313688 — intervention group
Group type: COMPARATOR
Intervention: Control participants (no arm weights)
Number of subjects: 0
Study 18313688 — intervention group
Group type: COMPARATOR
Intervention: Second control group (not specified)
Number of subjects: 0
Study 16481389 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan at a starting dose of 1.25 mg.m(‐2) with individual dose adjustment, administered intravenously on days 1‐5, every 21 days, for up to six courses.
Number of subjects: 170
Study 12900586 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard cuff
Number of subjects: 120
Study 12900586 — intervention group
Group type: COMPARATOR
Intervention: Large cuff
Number of subjects: 120
Study 9491720 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagotomy with pyloroplasty
Number of subjects: 230
Study 9491720 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective proximal vagotomy with duodenoplasty
Number of subjects: 230
Study 8473721 — intervention group
Group type: EXPERIMENTAL
Intervention: d-fenfluramine
Number of subjects: 12
Study 8473721 — intervention group
Group type: EXPERIMENTAL
Intervention: l-fenfluramine
Number of subjects: 12
Study 8473721 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 12
Study 8473721 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 3906545 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus intravenous piperacillin
Number of subjects: 18
Study 3906545 — intervention group
Group type: COMPARATOR
Intervention: Standard antibiotic treatment (flucloxacillin plus tobramycin)
Number of subjects: 18
Study 29995217 — intervention group
Group type: COMPARATOR
Intervention: HPV self-sampling delivered via US mail (SS + Mail)
Number of subjects: 600
Study 29995217 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV self-sampling delivered in-person by a community health worker (IP + SS)
Number of subjects: 600
Study 27136416 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting state functional connectivity (RSFC) in adolescents with remitted MDD (rMDD)
Number of subjects: 23
Study 27136416 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 23
Study 25260436 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline left atrial global longitudinal strain (LAεtotal) < 23.2%
Number of subjects: 256
Study 25260436 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline left atrial global longitudinal strain (LAεtotal)
Number of subjects: 256
Study 25260436 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients maintained sinus rhythm after catheter ablation
Number of subjects: 256
Study 23801099 — intervention group
Group type: EXPERIMENTAL
Intervention: Shallow trochlea (depth ≤3 mm)
Number of subjects: 304
Study 23801099 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal medial-to-lateral facet ratio (<0.4)
Number of subjects: 304
Study 23801099 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal sulcus angle (>170°)
Number of subjects: 304
Study 20534223 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC (50 mg/kg) bolus just before renal artery declamping (group N)
Number of subjects: 140
Study 20534223 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC (50 mg/kg) bolus plus fenoldopam (0.1 microg/kg/min) continuous infusion (group NF)
Number of subjects: 140
Study 20534223 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC (50 mg/kg) bolus plus dopamine (3 microg/kg/min) continuous infusion (group ND)
Number of subjects: 140
Study 20534223 — intervention group
Group type: COMPARATOR
Intervention: No NAC or other infusion (group C)
Number of subjects: 140
Study 17637608 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic cannabis use
Number of subjects: 0
Study 17637608 — intervention group
Group type: COMPARATOR
Intervention: Drug-naive controls
Number of subjects: 0
Study 16177613 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-hand training (RIGHT)
Number of subjects: 39
Study 16177613 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-hand training (LEFT)
Number of subjects: 39
Study 16177613 — intervention group
Group type: COMPARATOR
Intervention: Nontraining control (CON)
Number of subjects: 39
Study 16177613 — intervention group
Group type: EXPERIMENTAL
Intervention: RIGHT and LEFT combined
Number of subjects: 39
Study 16177613 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained limb agonist EMG activation
Number of subjects: 39
Study 16177613 — intervention group
Group type: EXPERIMENTAL
Intervention: Untrained limb EMG
Number of subjects: 39
Study 12680882 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 3 x 25 mg day-1
Number of subjects: 16
Study 12680882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 10535657 — intervention group
Group type: EXPERIMENTAL
Intervention: ST+MI (standard treatment plus motivational interviewing)
Number of subjects: 121
Study 10535657 — intervention group
Group type: COMPARATOR
Intervention: ST (standard treatment)
Number of subjects: 121
Study 8735864 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiorphan (1.25 mg/mL, 0.5 mL)
Number of subjects: 9
Study 8735864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 1799915 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil 100 mg orally with food every 12 hours
Number of subjects: 93
Study 1799915 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V potassium 250 mg orally on an empty stomach every six hours
Number of subjects: 93
Study 375847 — intervention group
Group type: EXPERIMENTAL
Intervention: levamisole
Number of subjects: 29
Study 31694849 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message reminders plus routine care
Number of subjects: 434
Study 31694849 — intervention group
Group type: COMPARATOR
Intervention: Routine care only
Number of subjects: 434
Study 27672018 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane-remifentanil
Number of subjects: 100
Study 27672018 — intervention group
Group type: COMPARATOR
Intervention: Propofol-remifentanil
Number of subjects: 100
Study 25800756 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal (IP) chemotherapy
Number of subjects: 876
Study 25800756 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) therapy
Number of subjects: 876
Study 23862834 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral hearing aids
Number of subjects: 0
Study 23862834 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral hearing aids
Number of subjects: 0
Study 23862834 — intervention group
Group type: COMPARATOR
Intervention: Hearing aids (both unilateral and bilateral)
Number of subjects: 0
Study 21840137 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly cisplatin 40 mg/m(2), six cycles
Number of subjects: 104
Study 21840137 — intervention group
Group type: COMPARATOR
Intervention: Triweekly cisplatin 75 mg/m(2) every 3 weeks, three cycles
Number of subjects: 104
Study 19606944 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliphatic polyester terpolymers with LA:CL:GA composition of 3:1:1
Number of subjects: 0
Study 19606944 — intervention group
Group type: COMPARATOR
Intervention: PLLA homopolymers
Number of subjects: 0
Study 17107240 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex ER
Number of subjects: 377
Study 17107240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 377
Study 15608761 — intervention group
Group type: EXPERIMENTAL
Intervention: Curamed colostrum tablets
Number of subjects: 148
Study 15608761 — intervention group
Group type: EXPERIMENTAL
Intervention: Other brand of colostrum tablets
Number of subjects: 148
Study 15608761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 12567750 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon 5 (sodium hyaluronate 5,000 2.3%)
Number of subjects: 90
Study 12567750 — intervention group
Group type: COMPARATOR
Intervention: Healon GV (sodium hyaluronate 7,000 1.4%)
Number of subjects: 90
Study 12567750 — intervention group
Group type: COMPARATOR
Intervention: Iviz (sodium hyaluronate 1.0%)
Number of subjects: 90
Study 12567750 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study 9454546 — intervention group
Group type: EXPERIMENTAL
Intervention: Bassini repair technique
Number of subjects: 30
Study 9454546 — intervention group
Group type: COMPARATOR
Intervention: Trabucco's operation
Number of subjects: 30